Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
9.24
Dollar change
+1.35
Percentage change
17.11
%
Index- P/E- EPS (ttm)-163.48 Insider Own8.81% Shs Outstand- Perf Week57.68%
Market Cap6.19M Forward P/E- EPS next Y-3.99 Insider Trans-15.43% Shs Float0.62M Perf Month74.34%
Income-15.91M PEG- EPS next Q-2.15 Inst Own12.21% Short Float5.71% Perf Quarter92.50%
Sales0.00M P/S- EPS this Y89.22% Inst Trans- Short Ratio0.05 Perf Half Y54.00%
Book/sh4.87 P/B1.90 EPS next Y21.30% ROA-296.61% Short Interest0.04M Perf Year-87.09%
Cash/sh4.91 P/C1.88 EPS next 5Y- ROE-3139.91% 52W Range2.75 - 85.00 Perf YTD120.00%
Dividend Est.- P/FCF- EPS past 5Y60.56% ROI-461.83% 52W High-89.13% Beta1.28
Dividend TTM- Quick Ratio1.60 Sales past 5Y0.00% Gross Margin- 52W Low236.00% ATR (14)0.66
Dividend Ex-Date- Current Ratio1.60 EPS Y/Y TTM97.55% Oper. Margin0.00% RSI (14)83.79 Volatility13.02% 9.32%
Employees10 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price40.00
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q-102.53% Payout- Rel Volume0.32 Prev Close7.89
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume746.60K Price9.24
SMA2064.44% SMA5091.27% SMA200-26.12% Trades Volume236,614 Change17.11%
Feb-13-24 07:00AM
Jan-23-24 07:00AM
Jan-17-24 07:00AM
Jan-04-24 06:00AM
Dec-27-23 11:55AM
10:29AM Loading…
10:29AM
06:00AM
Dec-20-23 10:03AM
10:03AM
Dec-18-23 06:00AM
Dec-14-23 09:15AM
Dec-06-23 07:00AM
Dec-05-23 07:00AM
Oct-10-23 07:00AM
Oct-03-23 07:00AM
08:45AM Loading…
Sep-15-23 08:45AM
Sep-14-23 10:43AM
06:00AM
Sep-05-23 07:00AM
Jul-19-23 08:15AM
Jul-13-23 07:00AM
Jul-05-23 07:00AM
Jun-28-23 07:00AM
Jun-27-23 07:00AM
Jun-15-23 11:31AM
Jun-13-23 12:50PM
07:00AM
May-15-23 07:00AM
May-11-23 07:00AM
May-02-23 07:30AM
07:00AM Loading…
Apr-25-23 07:00AM
Mar-13-23 08:00AM
07:00AM
Mar-10-23 07:00AM
Mar-09-23 07:00AM
Feb-28-23 07:00AM
Feb-21-23 07:00AM
Feb-13-23 07:00AM
Feb-07-23 07:00AM
Feb-02-23 07:00AM
Jan-31-23 07:00AM
Jan-30-23 07:00AM
Jan-25-23 07:00AM
Jan-24-23 07:00AM
Jan-13-23 04:00PM
10:20AM
Jan-09-23 09:10AM
Jan-05-23 09:45AM
Dec-12-22 07:30AM
Dec-05-22 07:00AM
Nov-30-22 07:00AM
Nov-25-22 05:45PM
Nov-22-22 04:15PM
Nov-21-22 08:00AM
Nov-16-22 07:00AM
Oct-31-22 07:00AM
Oct-11-22 05:30PM
Oct-10-22 07:00AM
Oct-06-22 09:00PM
08:05AM
Sep-28-22 07:00AM
Sep-19-22 07:00AM
Sep-14-22 07:00AM
Sep-07-22 07:00AM
Aug-31-22 07:00AM
Aug-29-22 07:00AM
Aug-25-22 12:00PM
Jul-15-22 08:00AM
May-17-22 07:00AM
Apr-29-22 04:30PM
Apr-27-22 07:00AM
Mar-31-22 08:15AM
Mar-28-22 04:23PM
Mar-22-22 07:00AM
Mar-08-22 07:00AM
Mar-03-22 07:00AM
Mar-02-22 05:00PM
Mar-01-22 07:00AM
Feb-28-22 08:01AM
Feb-07-22 07:30AM
Jan-17-22 10:30AM
Jan-14-22 11:25AM
09:00AM
Jan-13-22 07:00AM
Jan-07-22 09:16AM
Jan-06-22 07:00AM
Jan-04-22 07:00AM
Dec-27-21 02:00PM
Dec-23-21 11:45AM
Dec-17-21 09:06AM
Dec-13-21 07:00AM
Dec-09-21 07:00AM
Dec-06-21 07:00AM
Nov-30-21 07:00AM
Nov-16-21 07:00AM
Oct-21-21 07:30AM
Oct-19-21 09:24AM
Oct-14-21 09:00AM
Oct-12-21 08:30AM
Oct-04-21 11:45AM
First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAPIRSTEIN JAMESChairman, President and CEOJan 12Sale4.2016669739,166Jan 17 04:01 PM
Romano SarahChief Financial OfficerJan 12Sale4.209841220,306Jan 17 04:02 PM
SAPIRSTEIN JAMESPresident and CEOOct 04Sale0.292,76480233,397Oct 06 04:04 PM
Romano SarahChief Financial OfficerOct 04Sale0.291,67648615,800Oct 06 04:05 PM
CASAMENTO CHARLES JDirectorSep 15Sale0.431046,098Sep 18 05:44 PM
CASAMENTO CHARLES JDirectorAug 31Sale0.306,0531,8166,108Sep 05 08:08 PM
SAPIRSTEIN JAMESPresident and CEOJul 03Sale1.543,3495,15736,161Jul 05 04:27 PM
Romano SarahChief Financial OfficerJul 03Sale1.541,9773,04517,476Jul 05 04:28 PM
SAPIRSTEIN JAMESPresident and CEOApr 03Sale2.503,3478,36839,510Apr 05 04:07 PM
Romano SarahChief Financial OfficerApr 03Sale2.501,9754,93819,453Apr 05 04:17 PM